ea0090ep848 | Pituitary and Neuroendocrinology | ECE2023
Serban Andreea
, Zampetti Benedetta
, Saladino Andrea
, Chiodini Iacopo
, Cozzi Renato
Pasireotide (Pas) is a multireceptor-targeted somatostatin analogue approved for the treatment of patients with Cushings Disease (CD) who fail or are poor candidates to surgery. Pas markedly improves signs and symptoms of the disease, reduces urinary free cortisol (UFC) up to its normalization in 55% of patients and pituitary tumour size in up to 100%. Here we present a patient with severe recurrent CD treated with Pas and showing opposite results between hormonal levels...